Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

755 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up.
Salehi M, Alavi Darazam I, Nematollahi A, Alimohammadi M, Pouya S, Alimohammadi R, Khajavirad N, Porgoo M, Sedghi M, Mahdi Sepahi M, Azimi M, Hosseini H, Mahmoud Hashemi S, Dehghanizadeh S, Khoddami V. Salehi M, et al. Among authors: hosseini h. Int Immunopharmacol. 2024 Jun 15;134:112192. doi: 10.1016/j.intimp.2024.112192. Epub 2024 May 17. Int Immunopharmacol. 2024. PMID: 38761778 Clinical Trial.
Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial.
Malekzadeh R, Abedini A, Mohsenpour B, Sharifipour E, Ghasemian R, Javad-Mousavi SA, Khodashahi R, Darban M, Kalantari S, Abdollahi N, Salehi MR, Rezaei Hosseinabadi A, Khorvash F, Valizadeh M, Dastan F, Yousefian S, Hosseini H, Anjidani N, Tabarsi P. Malekzadeh R, et al. Among authors: hosseini h. Int Immunopharmacol. 2020 Dec;89(Pt B):107102. doi: 10.1016/j.intimp.2020.107102. Epub 2020 Oct 13. Int Immunopharmacol. 2020. PMID: 33075713 Free PMC article. Clinical Trial.
Assessment of BIV1-CovIran inactivated vaccine-elicited neutralizing antibody against the emerging SARS-CoV-2 variants of concern.
Salehi M, Hosseini H, Jamshidi HR, Jalili H, Tabarsi P, Mohraz M, Karimi H, Lotfinia M, Aalizadeh R, Mohammadi M, Ramazi S, Abdoli A. Salehi M, et al. Among authors: hosseini h. Clin Microbiol Infect. 2022 Jun;28(6):882.e1-882.e7. doi: 10.1016/j.cmi.2022.02.030. Epub 2022 Mar 3. Clin Microbiol Infect. 2022. PMID: 35248745 Free PMC article.
Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults.
Mohraz M, Salehi M, Tabarsi P, Abbasi-Kangevari M, Ghamari SH, Ghasemi E, Amini Pouya M, Rezaei N, Ahmadi N, Heidari K, Malekpour MR, Nasiri M, Amirzargar AA, Saeedi Moghaddam S, Larijani B, Hosseini H. Mohraz M, et al. Among authors: hosseini h. BMJ Open. 2022 Apr 8;12(4):e056872. doi: 10.1136/bmjopen-2021-056872. BMJ Open. 2022. PMID: 35396297 Free PMC article. Clinical Trial.
Efficacy and safety of an inactivated virus-particle vaccine for SARS-CoV-2, BIV1-CovIran: randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial.
Mohraz M, Vahdat K, Ghamari SH, Abbasi-Kangevari M, Ghasemi E, Ghabdian Y, Rezaei N, Pouya MA, Abdoli A, Malekpour MR, Koohgir K, Saeedi Moghaddam S, Tabarsi P, Moghadami M, Khorvash F, Khodashahi R, Salehi M, Hosseini H. Mohraz M, et al. Among authors: hosseini h. BMJ. 2023 Sep 21;382:e070464. doi: 10.1136/bmj-2023-070464. BMJ. 2023. PMID: 37734752 Free PMC article. Clinical Trial.
Immunogenicity and safety evaluation of a newly manufactured recombinant Baculovirus-Expressed quadrivalent influenza vaccine in adults 18 years old and Above: An Open-Label, phase III extension study.
Shahri MS, Sadeghi S, Hazegh Fetratjoo D, Hosseini H, Amin Ghobadi M, Afshani SM, Mirhassani R, Gohari K, Havasi F, Abdolghaffari A, Hedayatjoo B, Ghanei M. Shahri MS, et al. Among authors: hosseini h. Int Immunopharmacol. 2024 Jul 30;136:112214. doi: 10.1016/j.intimp.2024.112214. Epub 2024 May 31. Int Immunopharmacol. 2024. PMID: 38823176 Clinical Trial.
Immunogenicity and safety of a bivalent, adjuvant system 04-adjuvanted human papillomavirus vaccine in healthy female volunteers aged 15-25: a randomized, double-blind, phase III, noninferiority clinical trial.
Afshani SM, Mirhassani R, Hosseini H, Hosseini R, Tehranian A, Malekzadeh R, Ostovar A, Abdolghaffari AH, Ghobadi MA, Hedayatjoo B, Hazegh Fetratjoo D, Rezagholi Z, Anari A, Moini A. Afshani SM, et al. Among authors: hosseini r, hosseini h. Eur J Cancer Prev. 2022 Nov 1;31(6):558-567. doi: 10.1097/CEJ.0000000000000753. Epub 2022 Mar 29. Eur J Cancer Prev. 2022. PMID: 35352698 Clinical Trial.
Efficacy and safety of "Jollab Monzej" as a traditional persian compound medicine for the treatment of multiple sclerosis-related fatigue: A randomized placebo-controlled trial.
Yousefnia Babaki F, Khodadoost M, Rezaeizadeh H, Naser Moghadasi A, Fahimi S, Hosseini H, Movahhed M, Gharagozli K. Yousefnia Babaki F, et al. Among authors: hosseini h. Caspian J Intern Med. 2023 Spring;14(2):257-266. doi: 10.22088/cjim.14.2.257. Caspian J Intern Med. 2023. PMID: 37223302 Free PMC article.
755 results